These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 31053410)

  • 1. Probable sirolimus-induced rupture of arterial anastomosis after liver transplantation in a patient intolerant of tacrolimus.
    Lao MY; Ma T; Bai XL; Zhang XZ; Tang TY; Liang TB
    Hepatobiliary Pancreat Dis Int; 2019 Aug; 18(4):398-400. PubMed ID: 31053410
    [No Abstract]   [Full Text] [Related]  

  • 2. Impact of sirolimus on the recurrence of hepatocellular carcinoma after liver transplantation.
    Chinnakotla S; Davis GL; Vasani S; Kim P; Tomiyama K; Sanchez E; Onaca N; Goldstein R; Levy M; Klintmalm GB
    Liver Transpl; 2009 Dec; 15(12):1834-42. PubMed ID: 19938137
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sirolimus-based immunosuppression following liver transplantation for hepatocellular carcinoma.
    Zimmerman MA; Trotter JF; Wachs M; Bak T; Campsen J; Skibba A; Kam I
    Liver Transpl; 2008 May; 14(5):633-8. PubMed ID: 18324656
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sirolimus-based immunosuppression therapy in liver transplantation for patients with hepatocellular carcinoma exceeding the Milan criteria.
    Zhou J; Wang Z; Wu ZQ; Qiu SJ; Yu Y; Huang XW; Tang ZY; Fan J
    Transplant Proc; 2008 Dec; 40(10):3548-53. PubMed ID: 19100435
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Everolimus-based immunosuppression in a case of ABO-incompatible liver transplantation with calcineurin inhibitor-related posterior occipital syndrome.
    Catalano G; De Simone P; Mazzoni A; Ghinolfi D; Coletti L; Filipponi F
    Transpl Int; 2014 Sep; 27(9):e84-6. PubMed ID: 24606320
    [No Abstract]   [Full Text] [Related]  

  • 6. Liver transplantation for hepatocellular carcinoma under calcineurin inhibitors: reassessment of risk factors for tumor recurrence.
    Vivarelli M; Cucchetti A; La Barba G; Ravaioli M; Del Gaudio M; Lauro A; Grazi GL; Pinna AD
    Ann Surg; 2008 Nov; 248(5):857-62. PubMed ID: 18948815
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of sirolimus and tacrolimus on mortality and graft loss in liver transplant recipients with or without hepatitis C virus: an analysis of the Scientific Registry of Transplant Recipients Database.
    Watt KD; Dierkhising R; Heimbach JK; Charlton MR
    Liver Transpl; 2012 Sep; 18(9):1029-36. PubMed ID: 22641474
    [TBL] [Abstract][Full Text] [Related]  

  • 8. De novo sirolimus-based immunosuppression after liver transplantation for hepatocellular carcinoma: long-term outcomes and side effects.
    Toso C; Meeberg GA; Bigam DL; Oberholzer J; Shapiro AM; Gutfreund K; Ma MM; Mason AL; Wong WW; Bain VG; Kneteman NM
    Transplantation; 2007 May; 83(9):1162-8. PubMed ID: 17496530
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sirolimus Use in Liver Transplant Recipients With Hepatocellular Carcinoma: A Randomized, Multicenter, Open-Label Phase 3 Trial.
    Geissler EK; Schnitzbauer AA; Zülke C; Lamby PE; Proneth A; Duvoux C; Burra P; Jauch KW; Rentsch M; Ganten TM; Schmidt J; Settmacher U; Heise M; Rossi G; Cillo U; Kneteman N; Adam R; van Hoek B; Bachellier P; Wolf P; Rostaing L; Bechstein WO; Rizell M; Powell J; Hidalgo E; Gugenheim J; Wolters H; Brockmann J; Roy A; Mutzbauer I; Schlitt A; Beckebaum S; Graeb C; Nadalin S; Valente U; Turrión VS; Jamieson N; Scholz T; Colledan M; Fändrich F; Becker T; Söderdahl G; Chazouillères O; Mäkisalo H; Pageaux GP; Steininger R; Soliman T; de Jong KP; Pirenne J; Margreiter R; Pratschke J; Pinna AD; Hauss J; Schreiber S; Strasser S; Klempnauer J; Troisi RI; Bhoori S; Lerut J; Bilbao I; Klein CG; Königsrainer A; Mirza DF; Otto G; Mazzaferro V; Neuhaus P; Schlitt HJ
    Transplantation; 2016 Jan; 100(1):116-25. PubMed ID: 26555945
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of different immunosuppressive schedules on recurrence-free survival after liver transplantation for hepatocellular carcinoma.
    Vivarelli M; Dazzi A; Zanello M; Cucchetti A; Cescon M; Ravaioli M; Del Gaudio M; Lauro A; Grazi GL; Pinna AD
    Transplantation; 2010 Jan; 89(2):227-31. PubMed ID: 20098287
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sirolimus as rescue therapy after liver transplantation.
    Reigada CH; de Ataide EC; de Araújo FR; Ramos AP; Stucchi RS; Eescanhoela CA; Boin IF
    Transplant Proc; 2012 Oct; 44(8):2434-7. PubMed ID: 23026613
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment for the recurrence of hepatocellular carcinoma following liver transplantation: what is the best strategy?
    Shi YH; Zhou J; Fan J
    Cancer Biol Ther; 2009 Apr; 8(7):22-4. PubMed ID: 19417558
    [No Abstract]   [Full Text] [Related]  

  • 13. Recurrence of migraine with aura due to tacrolimus therapy in a liver transplant recipient successfully treated with sirolimus substitution.
    Toth CC; Burak K; Becker W
    Headache; 2005 Mar; 45(3):245-6. PubMed ID: 15836601
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Conversion to sirolimus immunosuppression in liver transplantation recipients with hepatocellular carcinoma: Report of an initial experience.
    Zhou J; Fan J; Wang Z; Wu ZQ; Qiu SJ; Huang XW; Yu Y; Sun J; Xiao YS; He YF; Wang YQ; Tang ZY
    World J Gastroenterol; 2006 May; 12(19):3114-8. PubMed ID: 16718799
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [A retrospective cohort study regarding the effect of sirolimus-based immunosuppression protocol on the long-term survival of hepatocellular carcinoma patients after liver transplantation].
    Zhao X; Lu S; Wang M; Wu J; Lin D; Guo Q; Lai W; Zeng D; Li C; Liu Y; Sun L; Yan D; Li N
    Zhonghua Wai Ke Za Zhi; 2014 Apr; 52(4):245-8. PubMed ID: 24924566
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A retrospective study of conversion from tacrolimus-based to sirolimus-based immunosuppression in orthotopic liver transplant recipients.
    Yu S; He X; Yang L; Ma Y; Zhu X; Ju W; Huang J
    Exp Clin Transplant; 2008 Jun; 6(2):113-7. PubMed ID: 18816237
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sirolimus-based immunosuppression for liver transplantation in the presence of extended criteria for hepatocellular carcinoma.
    Kneteman NM; Oberholzer J; Al Saghier M; Meeberg GA; Blitz M; Ma MM; Wong WW; Gutfreund K; Mason AL; Jewell LD; Shapiro AM; Bain VG; Bigam DL
    Liver Transpl; 2004 Oct; 10(10):1301-11. PubMed ID: 15376305
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comment: delayed wound healing with sirolimus after liver transplant.
    Mathis AS
    Ann Pharmacother; 2003 Mar; 37(3):453. PubMed ID: 12639183
    [No Abstract]   [Full Text] [Related]  

  • 19. Successful use of sirolimus in a patient with bulky ovarian metastasis of hepatocellular carcinoma after liver transplantation.
    Stippel DL; Kasper HU; Schleimer K; Töx U; Bangard C; Hölscher AH; Beckurts KT
    Transplant Proc; 2005 Jun; 37(5):2185-7. PubMed ID: 15964374
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized trial of tacrolimus in combination with sirolimus or mycophenolate mofetil in kidney transplantation: results at 6 months.
    Gonwa T; Mendez R; Yang HC; Weinstein S; Jensik S; Steinberg S;
    Transplantation; 2003 Apr; 75(8):1213-20. PubMed ID: 12717205
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.